COYA / Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal

Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, includ more_horizontal

Shares of Coya Therapeutics Inc. COYA, +3.33% gained 12% premarket on Wednesday after the clinical-stage biotech company released new data from a stud more_horizontal

Recently, IPO'd Coya has just reported cognition-improving and cognition-stabilizing results in an open label study in Alzheimer's patients with Coya more_horizontal

If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is more_horizontal

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing more_horizontal